

6. □Durrington PN, Hunt L, Ishola M & Kane J. Serum Apolipoproteins A1 and B lipoprotein in middle age men with and without previous myocardial infarction. *Br Heart J* 1986;56:206-12.
7. □Barter PJ, Ballentyne CM, Carmena R, Castro CM, Chapman MJ, Couture P. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty person/ten country panel. *J Intern Med*.2006;259:247-58.
8. □Miller NE, Hammett F, Saltissi S, et al. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. *Br Med J(Clin Res Ed)*. 1981;282:1741-44.
9. Maciejko JJ, Holmes DR, Kottke BA, et al. Apolipoprotein A-1 as a marker of angiographically assessed coronary artery disease. *N Engl J Med*. 1983;309:385-89.
10. Puchois P, Kandoussi A, Fievet P, et al. Apolipoprotein A1 containing lipoproteins in coronary artery disease. *Atherosclerosis*.1987;68:35-40.
11. Zambon A, Brown BG, Deeb SS, Brunzell JD. Genetics of Apo-B & A1 And premature CAD. *J Int Med*.2006;259:473-80.
12. □Stampfer MJ, sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins and the risk of myocardial infarction. *N Engl J Med*. 1991;325:373-81.
13. Buring JE, O'Connor GT, Goldhaber SZ, et al. Decreased HDL2 and HDL3 cholesterol, Apo A1 and Apo AII, and increased risk of myocardial infarction. *Circulation*.1992;85:22-29.
14. W, Steiner E. High Apolipoprotein B, Low Apolipoprotein A-1 and improvement in the prediction of fatal myocardial infarction (AMORIS Study) : a prospective study. *Lancet*.2001;358:2026-33.
15. Lamarche B, Moorjani S, Luplen PJ, et al. Apolipoprotein A1 and B levels and the risk of ischemic heart disease during a five year follow up of men in the Quebec Cardiovascular Study. *Circulation*1996;94:273-78.
16. □Talmud PJ, Hawe E, Miller GJ, Humphries SE. Non-fasting Apolipoprotein B and triglyceride level as a useful predictor of coronary heart disease risk in middle age UK men. *Arterioscler Thromb Vasc Boil*.2002;22:1918-23.
17. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. *Lancet*.2004; 364:937-52.
18. □ Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. *Clin Chem*.1974;20(4):470-75.
19. Trinder P. Enzymatic determination of TAG. *Ann Clinical Biochem*.1996;6:24-27.
20. □Burstein M, Scholnick HR & Morfin R. serum HDL-C estimation by phosphotungstate / magnesium method. *J Lipid Res*. 1970;11:583-92.
21. Freedman DS, Srinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GS. The relation of Apoprotein A1 and B in children to parental myocardial infarction. *N Eng J Med*.1986;315:721-26.
22. Lopes-virella MFL, Virella G and Evans G. Immunonephelometric Assay of Human Apolipoprotein A1. *Clin Chem* 1980;26(8):1205-08
23. Heuck CC & Schlier G. Nephelometry of Apolipoprotein B in Human serum. *Clin Chem*1979; 25(1) : 221-26.
24. □Vanistiphout WA HJ, Hofman A, Kruijssen HACM & Vermeeren R. Is the ratio of Apo B / Apo A1 an early predictor of coronary atherosclerosis ? *Atherosclerosis* 1986;62:179-82.
25. □Kukita H, Hamada M, Hiwada K, Kokubu T. Clinical significance of measurement of serum apolipoprotein A1, A11 and B in hypertriglyceridemic male patients with or without coronary artery diseases. *Atherosclerosis* 1985;55:143-49.
26. Al-Muhtaseb N, Hayet N & Al-Khafaji M. Lipoprotein and apolipoprotein in young male survivors of myocardial infarction. *Atherosclerosis* 1989;77(2-3);131-38.
27. Durrington PN, Hunt L, Ishola M & Arrol S. Apolipoproteins(a) A1 and B and parental history in men with early onset ischemic heart disease. *Lancet* 1988;14:1070-73.
28. Genest J, Mcnamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, Wilson PWF. Lipoprotein Cholesterol, Apolipoprotein A1 and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. *J Am Coll Cardiol*;1992:19:792-802.
29. □Gardner CD, Fortmann SP, Krauss RM; Apo B / Apo A1 ratio is more robust an specific marker. *JAMA*. 1996;276:875-81.
30. Mahly RW. Atherogenic hyperlipoproteinemia : the cellular and molecular biology of plasma lipoprotein altered by dietary fat and cholesterol. *Md Clin North Am*. 1982;66:375.
31. Stein EA, Myers GL. Lipids apolipoproteins and lipoprotein. In: Burtis CA, Ashwood ER, editors. *Tietz Fundamental Clinical Chemistry*. 4th ed. USA. WB Saunders Company. 1996:379-84.
32. Mayes PA, Botham KM. Lipid transport and storage. In: Murry RK, Granner DK, Mayer PA, Rodwell VW, editors. *Harper's illustrated Biochemistry*. 26th ed. USA. Mc Graw Hill. 2003:205-18.